Dainippon Sumitomo Eyes Mass Production Of Cell Sheets For Diseases
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma is working on mass-production technologies that would allow it to make sheets of induced pluripotent stem cells for retinal disease, with a launch target of 2018.